Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
First-line combination of an antibody–drug conjugate plus immunotherapy shows promise in non-small cell lung cancer
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
Rare cancers: research progresses at a slower pace than in other areas of oncology
With its new peer-reviewed journal dedicated to rare tumours, ESMO supports knowledge and data sharing among the stakeholders in the field
Novel data continue to support the use of perioperative durvalumab with neoadjuvant chemotherapy in bladder cancer
Additional analysis from the NIAGARA study were presented
Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+/HER2– breast cancer compared to chemotherapy
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Clinical benefits shown with pembrolizumab plus chemotherapy regardless bevacizumab use in advanced or recurrent cervical cancer
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
Long-term follow up data confirms the benefits of perioperative pembrolizumab in early-stage NSCLC
In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
An oncolytic adenovirus shows promise in inducing immune response in prostate cancer
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones